R. Brad Jones

7.5k total citations · 1 hit paper
107 papers, 3.4k citations indexed

About

R. Brad Jones is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, R. Brad Jones has authored 107 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Virology, 68 papers in Immunology and 35 papers in Infectious Diseases. Recurrent topics in R. Brad Jones's work include HIV Research and Treatment (80 papers), Immune Cell Function and Interaction (55 papers) and HIV/AIDS drug development and treatment (24 papers). R. Brad Jones is often cited by papers focused on HIV Research and Treatment (80 papers), Immune Cell Function and Interaction (55 papers) and HIV/AIDS drug development and treatment (24 papers). R. Brad Jones collaborates with scholars based in United States, Canada and Japan. R. Brad Jones's co-authors include Douglas F. Nixon, Mario Ostrowski, Bruce D. Walker, Colin Kovacs, Lishomwa C. Ndhlovu, Erika Benko, Aashish R. Jha, Tsuyoshi Fujita, Brian Long and Lewis L. Lanier and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

R. Brad Jones

102 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape

2017 254 citations R. Brad Jones, Allison S. Thomas et al. profile →

Peers

Countries citing papers authored by R. Brad Jones

Since Specialization

Citations

This map shows the geographic impact of R. Brad Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Brad Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Brad Jones more than expected).

Fields of papers citing papers by R. Brad Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Brad Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Brad Jones. The network helps show where R. Brad Jones may publish in the future.

Co-authorship network of co-authors of R. Brad Jones

This figure shows the co-authorship network connecting the top 25 collaborators of R. Brad Jones. A scholar is included among the top collaborators of R. Brad Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Brad Jones. R. Brad Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8 ⁺ T cells during chronic HIV-1 infection 2025 ·Science Translational Medicine ·(unknown), (unknown), (unknown), (unknown), Haisheng Yu, (unknown), Xiuting He, (unknown), James Ahodantin, (unknown), Jianwen Chen, Xiaoxuan Fan, (unknown), (unknown), R. Brad Jones, Shyam Kottilil, Poonam Mathur, Lishan Su	0
2	The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2 2024 ·JCI Insight ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marta Sanz, Dennis C. Copertino, Weisheng Wang, Natalia Soriano-Sarabia, R. Brad Jones, Alberto Bosque	2
3	Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy 2024 ·The Journal of Immunology ·(unknown), (unknown), (unknown), Arlene Bullotta, Evgenia Aga, Ronald J. Bosch, R. Brad Jones, Joseph J. Eron, John W. Mellors, Rajesh T. Gandhi, Deborah K. McMahon, Bernard Macatangay, Charles R. Rinaldo, Robbie B. Mailliard	1
4	HIV reservoirs are dominated by genetically younger and clonally enriched proviruses 2023 ·mBio ·Natalie N. Kinloch, Aniqa Shahid, Winnie Dong, (unknown), Bradley R. Jones, (unknown), (unknown), Guinevere Q. Lee, Talia M. Mota, Hanwei Sudderuddin, (unknown), Marianne Harris, Chanson J. Brumme, R. Brad Jones, Mark A. Brockman, Jeffrey B. Joy, Zabrina L. Brumme	9
5	Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV 2023 ·International Journal of Nanomedicine ·(unknown), (unknown), Jie Chen, Preethi B. Balakrishnan, Allison B. Powell, Kondareddy Cherukula, Carolina Colli Cruz, R. Brad Jones, Rebecca M. Lynch, Elizabeth E. Sweeney, Rohan Fernandes	1
6	Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins 2022 ·Proceedings of the National Academy of Sciences ·Fengwen Zhang, Trinity Zang, (unknown), Xiao Lei, Dennis C. Copertino, Talia M. Mota, Julie Boucau, Wilfredo F. García-Beltrán, R. Brad Jones, Paul D. Bieniasz	18
7	No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART 2022 ·AIDS ·Adam R. Ward, Allison S. Thomas, (unknown), Szu-Han Huang, Sheila M. Keating, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Bernard Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, R. Brad Jones	3
8	Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients 2022 ·Open Forum Infectious Diseases ·M. Veronica Dioverti, David C. Gaston, C. Paul Morris, Carol Ann Huff, Tania Jain, R. Brad Jones, Viki Anders, Howard M. Lederman, (unknown), Heba H. Mostafa, Robin K. Avery	18
9	T cell receptor–targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice 2021 ·Journal of Clinical Investigation ·(unknown), S. Garforth, (unknown), Hang Su, (unknown), (unknown), (unknown), (unknown), R. Brad Jones, Ravit Arav‐Boger, Steven C. Almo, Harris Goldstein	18
10	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies 2021 ·The Journal of Experimental Medicine ·(unknown), Christiaan H. van Dorp, Ali Danesh, Adam R. Ward, Thomas R. Dilling, Talia M. Mota, Elizabeth Zale, (unknown), Shabnum Patel, Chanson J. Brumme, Winnie Dong, D. S. Jones, Thomas L. Andresen, Bruce D. Walker, Zabrina L. Brumme, Catherine M. Bollard, Alan S. Perelson, Darrell J. Irvine, R. Brad Jones	10
11	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results 2020 ·The Journal of Infectious Diseases ·Natalie N. Kinloch, Gordon Ritchie, Chanson J. Brumme, Winnie Dong, (unknown), Tanya Lawson, R. Brad Jones, Julio Montaner, Victor C. M. Leung, Marc G. Romney, Aleksandra Stefanovic, Nancy Matic, Christopher F. Lowe, Zabrina L. Brumme	65
12	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir 2020 ·The Journal of Immunology ·Noemia S. Lima, Hiroshi Takata, Szu-Han Huang, (unknown), Julie L. Mitchell, Stephen Blackmore, (unknown), (unknown), (unknown), Jean‐Pierre Routy, Nelson L. Michael, Victor Appay, R. Brad Jones, Lydie Trautmann	7
13	Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection 2020 ·PLoS Pathogens ·(unknown), Julie Frouard, Andrea Gramatica, Guorui Xie, Sushama Telwatte, Guinevere Q. Lee, Pavitra Roychoudhury, Roland Schwarzer, Xiaoyu Luo, Steven A. Yukl, Sulggi A. Lee, Rebecca Hoh, Steven G. Deeks, R. Brad Jones, Marielle Cavrois, Warner C. Greene, Nadia R. Roan	26
14	Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression 2019 ·PLoS Computational Biology ·Matthew L. Bendall, Miguel de Mulder Rougvie, L. Iñiguez, (unknown), Marcos Pérez‐Losada, Mario Ostrowski, R. Brad Jones, Lubbertus C. F. Mulder, Gustavo Reyes‐Terán, Keith A. Crandall, Christopher E. Ormsby, Douglas F. Nixon	110
15	Phylogenetic approach to recover integration dates of latent HIV sequences within-host 2018 ·Proceedings of the National Academy of Sciences ·Bradley R. Jones, Natalie N. Kinloch, (unknown), (unknown), Marianne Harris, P. Richard Harrigan, R. Brad Jones, Mark A. Brockman, Jeffrey B. Joy, Art F. Y. Poon, Zabrina L. Brumme	39
16	Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus 2018 ·AIDS Research and Human Retroviruses ·Amanda B. Macedo, (unknown), Laura Martins, (unknown), (unknown), Adam M. Spivak, Douglas F. Nixon, R. Brad Jones, Vicente Planelles, Alberto Bosque	20
17	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy 2017 ·PLoS Pathogens ·Allison S. Thomas, Kimberley Jones, Rajesh T. Gandhi, Deborah K. McMahon, Joshua C. Cyktor, Dora Chan, Szu-Han Huang, Ronald Truong, Alberto Bosque, Amanda B. Macedo, Colin Kovacs, Erika Benko, Joseph J. Eron, Ronald J. Bosch, Christina M. Lalama, Samuel J. Simmens, Bruce D. Walker, John W. Mellors, R. Brad Jones	33
18	Short Communication: HIV Type 1 Accumulates in Influenza-Specific T Cells in Subjects Receiving Seasonal Vaccination in the Context of Effective Antiretroviral Therapy 2012 ·AIDS Research and Human Retroviruses ·R. Brad Jones, Colin Kovacs, Tae‐Wook Chun, Mario Ostrowski	8
19	Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy 2012 ·Mucosal Immunology ·Prameet M. Sheth, Tae Joon Yi, Colin Kovacs, Kimdar Sherefa Kemal, R. Brad Jones, B. Osborne, Richard Pilon, Charles la Porte, Mario Ostrowski, Tony Mazzulli, Harold Burger, Barbara Weiser, Rupert Kaul	23
20	Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition 2008 ·PLoS ONE ·R. Brad Jones, Keith Garrison, Jessica C. Wong, (unknown), Douglas F. Nixon, Mario Ostrowski	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact